Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2007

Ambrx Allies with Merck & Co. in Type 2 Diabetes Drug Discovery Collaboration

  • Ambrx and Merck & Co. are collaborating on the development of a therapeutic protein with properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders.

    Both parties will utilize Ambrx' protein technology, ReCODE™, to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

    The collaboration includes an upfront and R&D payments from Merck. Additionally, Ambrx will be eligible to receive future milestone fees associated with research, development, and commercialization of a drug candidate along with royalties on net sales. The firm also has the right to exercise an end of Phase II profit sharing option.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »